These findings suggest that the changes in 5-hmC observed following 4-HT supplementation in breast cancer cells may be driven by TET3 or TET2 enzymes, and that these alterations are specific to GPER and ESR expression. This evidence concerns the gene ESR1 and breast carcinoma.